Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells

Journal of the National Cancer Institute

Volumn 107, Issue 1, 2015, Pages

  Mrizak, Dhafer ^a   Martin, Nathalie ^a   Barjon, Clément ^b   Jimenez Pailhes, Anne Sophie ^b   Mustapha, Rami ^a   Niki, Toshiro ^c,d   Guigay, Joël ^b   Pancré, Véronique ^a   De Launoit, Yvan ^a   Busson, Pierre ^b   Moralès, Olivier ^a   Delhem, Nadira ^a  

^a UNIV LILLE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c GalPharma Co Ltd   (Japan)

^d KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI CCL20 MONOCLONAL ANTIBODY; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; CCL20 PROTEIN, HUMAN; CCL20 PROTEIN, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; FOXP3 PROTEIN, MOUSE; IL10 PROTEIN, HUMAN; IL10 PROTEIN, MOUSE; IL2RA PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CD4+ CD25+ T LYMPHOCYTE; CELL ISOLATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PHENOTYPIC VARIATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SCID MOUSE; TUMOR EXOSOME; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CARCINOMA; CD4+ T LYMPHOCYTE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; NASOPHARYNX TUMOR; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL20; EXOSOMES; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, SCID; NASOPHARYNGEAL NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84925546909     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju363     Document Type: Article

References (39)

1. Bray F, Haugen M, Moger TA, Tretli S, Aalen OO, Grotmol T. Ageincidence curves of nasopharyngeal carcinoma worldwide: bimodality in low-risk populations and aetiologic implications. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2356-2365.
2. Chan AT. Nasopharyngeal carcinoma. Ann Oncol. 2010:21 Suppl 7: vii308-312.
3. Yap YY, Hassan S, Chan M, Choo PK, Ravichandran M. Epstein-Barr virus DNA detection in the diagnosis of nasopharyngeal carcinoma. Otolaryngol Head Neck Surg. 2007;136(6):986-991.
4. Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol. 1994;21(3):376-381.
5. Lu SJ, Day NE, Degos L, et al. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature. 1990;346(6283):470-471.
6. Zheng X, Yan L, Nilsson B, Eklund G, Drettner B. Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in southern China. Acta Oncol. 1994;33(8):867-872.
7. Gallicchio L, Matanoski G, Tao XG, et al. Adulthood consumption of preserved and nonpreserved vegetables and the risk of nasopharyngeal carcinoma: a systematic review. Int J Cancer. 2006;119(5):1125-1135.
8. Hildesheim A, Wang CP. Genetic predisposition factors and nasopharyngeal carcinoma risk: A review of epidemiological association studies, 2000-2011 Rosetta Stone for NPC: Genetics, viral infection, and other environmental factors. Semin Cancer Biol. 2012;22(2):107-116.
9. Busson P, Braham K, Ganem G, et al. Epstein-Barr virus-containing epithelial cells from nasopharyngeal carcinoma produce interleukin 1 alpha. Proceedings of the National Academy of Sciences of the United States of America. 1987;84(17):6262-6266.
10. Huang YT, Sheen TS, Chen CL, et al. Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD4+ T cells. Cancer Res. 1999;59(7):1599-1605.
11. Tang KF, Tan SY, Chan SH, et al. A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: implication for the intense tumor infiltration by T lymphocytes and macrophages. Human Pathol. 2001;32(1):42-49.
12. Teichmann M, Meyer B, Beck A, Niedobitek G. Expression of the interferon-inducible chemokine IP-10(CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. J Pathol. 2005;206(1):68-75.
13. Lau KM, Cheng SH, Lo KW, et al. Increase in circulating Foxp3+CD4+CD25 (high) regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer. 2007;96(4):617-622.
14. Pioche-Durieu C, Keryer C, Souquere S, et al. In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. J Virol. 2005;79(21):13326-13337.
15. Keryer-Bibens C, Pioche-Durieu C, Villemant C, et al. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer. 2006;6:283.
16. Hirashima M, Kashio Y, Nishi N, et al. Galectin-9 in physiological and pathological conditions. Glycoconj J. 2004;19(7-9):593-600.
17. Carter KL, Cahir-McFarland E, Kieff E. Epstein-barr virusinduced changes in B-lymphocyte gene expression. J Virol. 2002;76(20):10427-10436.
18. Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nature Immunol. 2005;6(12):1245-1252.
19. Klibi J, Niki T, Riedel A, et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood. 2009;113(9):1957-1966.
20. Miroux C, Morales O, Ghazal K et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation. 2012;94(2):123-127.
21. Moralès O, Depil S, Mrizak D, et al. EBV Latency II-derived peptides induce a specific CD4+ cytotoxic T-cell activity and not a CD4+ regulatory T-cell response. J Immunoth. 2012;35(3):254-266.
22. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods. 2001;25(4):402-408.
23. Chenivesse C, Chang Y, Azzaoui I, et al. Pulmonary CCL18 recruits human regulatory T cells. J Immunol. 2012;1;189(1):128-137.
24. Ho SY, Guo HR, Chen HH, Hsiao JR, Jin YT, Tsai ST. Prognostic implications of Fas-ligand expression in nasopharyngeal carcinoma. Head Neck. 2004;26(11):977-983.
25. Chaput N, Thery C. Exosomes: immune properties and potential clinical implementations. Semin Immunopathol. 2011;33(5):419-40.
26. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer. 2005;92(2):305-311.
27. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nature Rev. 2009;9(8):581-593.
28. Whiteside TL. Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system? Br J Cancer. 2005;92(2):209-211.
29. Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007;67(7):2912-2915.
30. Curiel TJ. Treg and rethinking cancer immunotherapy. J Clin Invest. 2007;117(5):1167-1174.
31. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99-146.
32. Liu VC, Wong LY, Jang T, et al. Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol. 2007;178(5):2883-2892.
33. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096-1103.
34. Wada J, Suzuki H, Fuchino R, et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res. 2009;29(3):881-888.
35. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev. 2006;6(4):295-307.
36. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127(4):759-767.
37. Mailloux AW, Young MR. Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit Rev Immunol. 2010;30(5):435-447.
38. Valzasina B, Piconese S, Guiducci C, Colombo MP. Tumorinduced expansion of regulatory T cells by conversion of CD4+CD25-lymphocytes is thymus and proliferation independent. Cancer Res. 2006;66(8):4488-4495.
39. Chang KP, Hao SP, Chang JH, et al. Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes. Clin Cancer Res. 2008;14(21):6979-6987.